Oramed Pharmaceuticals Inc.

NASDAQ:ORMP

Biotechnology

Healthcare
$3.89 +0.79%

+$0.03 today

Market cap
$169.16M
Beta
1.24
P/E (TTM)
1.4
EPS (TTM)
$2.70
Dividend yield
6.54%
52W Low $1.98High $5.01

Volume 0.16M

Average 0.16M

ORMP Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Oramed Pharmaceuticals Inc.NASDAQ: ORMP

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development declines year over year

Q1 FY2026 research & development of $1.59M fell 27.7% year over year, behind the -21.5% change in trailing-twelve-month research & development. Sequentially, it fell 19.8% from the prior quarter. Over 3 fiscal years it compounded at -38.7% a year.

Context

  • Research & development amounted to 319.1% of revenue in FY2025.
  • Research & development increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -27.7% toward the trailing-twelve-month pace of -21.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.59M-19.8% QoQ
Last fiscal yearDec 2025
$6.38M+0.9% YoY
LTMMar 2026
$5.77M-21.5% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-27.7%——
1 year+0.9%——
3-year CAGR-38.7%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
6.38M USD
Year-over-year change
+0.9%
4-year CAGR
-25.7%

Research & Development vs competitors

How ORMP compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -21.5% is the 8th highest of 11, against a peer median of -13.4%.
  • Over three fiscal years its annual growth of -38.7% compares with a peer median of -12.0%.
ORMP Competitors
Research & Development for ORMP and competitors
Company Period LTM YoY 3-year CAGR% of revenue
COYACoya Therapeutics, Inc.LTM Mar 2026$3.68B USD+26273.1%+50.2%46313.4%
MGNXMacroGenics, Inc.LTM Mar 2026$135.36M USD-19.9%-12.2%86.2%
CNTBConnect Biopharma Holdings LimitedFY2025$37.8M USD+29.2%-26.9%59059.4%
STTKShattuck Labs, Inc.LTM Mar 2026$36.3M USD-40.4%-24.8%3629.9%
CNTXContext Therapeutics Inc.LTM Mar 2026$35.41M USD+46.4%+65.0%—
KLRSKalaris Therapeutics IncLTM Mar 2026$32.3M USD-29.1%+37.8%—
IMAImageneBio IncLTM Mar 2026$30.77M USD+23.4%-23.7%—
OVIDOvid Therapeutics Inc.LTM Mar 2026$30.07M USD-8.9%+1.3%422.2%
IFRXInflaRx N.V.LTM Mar 2026€22.87M EUR-34.8%-11.8%77989.1%
CLNNClene Inc.LTM Mar 2026$12.86M USD-17.9%-24.0%9596.3%
ORMPOramed Pharmaceuticals Inc.LTM Mar 2026$5.77M USD-21.5%-38.7%—
Peer median (excluding ORMP) —-13.4%-12.0%9596.3%

Competitors are the stored peer set for ORMP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Aug 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue2.7M2.7M1.34M02M
Cost of Revenue000193K1.99M
Gross Profit2.7M2.7M1.34M(193K)13K
Gross Margin100.0%100.0%100.0%—0.7%
Research & Development20.99M27.64M8.97M6.32M6.38M
Selling, General & Admin5.94M15.66M8.14M6.46M8.72M
Operating Expenses26.93M43.3M17.11M12.78M15.1M
Depreciation & Amortization77K3.62M196K193K121K
EBITDA(25.04M)(36.98M)7.32M(14.87M)75.45M
EBITDA Margin-926.3%-1368.0%546.3%—3772.2%
Operating Income(24.22M)(40.6M)(15.77M)(12.78M)(15.09M)
Operating Margin-896.2%-1502.0%-1176.8%—-754.4%
Interest Income347K3.57M8.03M02.37M
Interest Expense6K03.58M853K0
Other Income / Expenses893K2.93M20.86M(3.14M)90.41M
Income Before Tax(22.99M)(37.66M)5.09M(15.92M)75.32M
Pre-Tax Margin-850.5%-1393.4%379.7%—3766.2%
Income Tax Expense(2.88M)100K03.18M11.31M
Net Income(22.24M)(37.76M)5.53M(19.1M)64.05M
Net Margin-822.7%-1397.1%412.3%—3202.5%
EPS (Basic)(0.78)(0.97)0.14(0.47)1.53
EPS (Diluted)(0.78)(0.97)0.14(0.47)1.50
Weighted Avg Shares28.47M39M40.32M40.83M41.4M
Weighted Avg Shares (Diluted)28.47M39M40.57M40.83M42.42M

Oramed Pharmaceuticals Inc.

NASDAQ:ORMP

Intrinsic Alpha fair value

Locked

Current Price

$3.89

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.